Navigation Links
Universal donor immune cells
Date:7/25/2011

One of the latest attempts to boost the body's defenses against cancer is called adoptive cell transfer, in which patients receive a therapeutic injection of their own immune cells. This therapy, currently tested in early clinical trials for melanoma and neuroblastoma, has its limitations: Removing immune cells from a patient and growing them outside the body for future re-injection is extremely expensive and not always technically feasible.

Weizmann Institute scientists have now tested in mice a new form of adoptive cell transfer, which overcomes these limitations while enhancing the tumor-fighting ability of the transferred cells. The research, reported recently in Blood, was performed in the lab of Prof. Zelig Eshhar of the Institute's Immunology Department, by graduate student Assaf Marcus and lab technician Tova Waks.

The new approach should be more readily applicable than existing adoptive cell transfer treatments because it relies on a donor pool of immune T cells that can be prepared in advance, rather than on the patient's own cells. Moreover, using a method pioneered by Prof. Eshhar more than two decades ago, these T cells are outfitted with receptors that specifically seek out and identify the tumor, thereby promoting its destruction.

In the study, the scientists first suppressed the immune system of mice with a relatively mild dose of radiation. They then administered a controlled dose of the modified donor T cells. The mild suppression temporarily prevented the donor T cells from being rejected by the recipient, but it didn't prevent the cells themselves from attacking the recipient's body, particularly the tumor. This approach was precisely what rendered the therapy so effective: The delay in the rejection of the donor T cells gave these cells sufficient opportunity to destroy the tumor.

If this method works in humans as well as it did in mice, it could lead to an affordable cell transfer therapy for a wide variety of cancers. Such therapy would rely on an off-the-shelf pool of donor T cells equipped with receptors for zeroing in on different types of cancerous cells.


'/>"/>

Contact: Yivsam Azgad
news@weizmann.ac.il
972-893-43856
Weizmann Institute of Science
Source:Eurekalert

Related biology news :

1. Discovery of natural antibody brings a universal flu vaccine a step closer
2. Johns Hopkins scientists expose cancer cells universal dark matter
3. Adjuvant combo shows potential for universal influenza vaccine
4. New report underlines the threat to universal access to HIV prevention, treatment and care due to a slow-down in treatment scale-up and waning political will
5. Human rights protections essential in drive for universal access
6. At opening of XVIII International AIDS Conference, scientific, community and political leaders applaud recent progress toward universal access and urge continued momentum to finish what weve started
7. New steps toward a universal flu vaccine
8. ASU scientists develop universal DNA reader to advance faster, cheaper sequencing efforts
9. Poorer diabetics receive worse care than other in countries with universal health coverage
10. Bug barcode readers hold out promise of universal vaccines
11. Biologists discover death stench is a universal ancient warning signal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/12/2017)... 2017 A new report by Allied Market Research, titled, "Global ... technology market is expected to generate revenue of $10.72 billion by 2022, with an ... Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) In the year ...
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... -- Bioptix, Inc. (Nasdaq: BIOP ... 14, 2017 the Board of Directors of the Company ... certain employees associated with the September 2016 acquisition of ... on January 16, 2017 and terminations are expected to ... severance benefits in certain circumstances of up to one ...
(Date:1/20/2017)... 2017 Stock-Callers.com explores the Biotech ... the most recent performances of select equities. In this ... RGLS ), Abeona Therapeutics Inc. (NASDAQ: ABEO ... and Sage Therapeutics Inc. (NASDAQ: SAGE ). ... Research, global Biotech market size is expected to reach $604.40 billion by 2020 ...
(Date:1/19/2017)... Research and Markets has announced the addition of the ... - Global Opportunity Analysis and Industry Forecast, 2014-2022" report to ... ... to reach $15,737 million by 2022 from $6,521 in 2015, growing ... Omic technologies segment accounted for more than half of the ...
(Date:1/19/2017)... Research and Markets ... has announced the addition of the ... 2025" report to their offering. Report ... provides a detailed analysis on current and future market trends to identify ... market values as the base numbers Key market trends ...
Breaking Biology Technology: